Undisclosed GLP-1R, GIPR, GCGR agonist / Septerna, Novo Nordisk - LARVOL DELTA

Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs (FierceBiotech) - "Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments for rights to preclinical oral small molecules that hit targets including GLP-1....Septerna’s discovery-stage programs are years behind Lilly, but the biotech has made the case that it has a unique feature that sets its molecules apart from the competition. Now, Septerna has the validation of a deal with Novo that is worth up to $2.2 billion across an upfront payment and milestones....Septerna has shared...mouse data on the GIP receptor agonist. Mice lost a little weight after taking the small molecule as a monotherapy, but the combination data are more compelling....Novo and Septerna will initially work on four development programs for small molecules aimed at one or more targets, including GLP-1, GIP and glucagon."

Licensing / partnership • Preclinical • Obesity